Clinical Efficacy Analysis of Salbutamol Plus Budesonide in Asthma and COPD Overlap Syndrome
Objective To evaluate the clinical efficacy of salbutamol and budesonide in asthma and COPD overlap syndrome.Methods A total of 84 patients with asthma and COPD overlap syndrome admitted to the First People's Hospital of Jinan from January 2022 to November 2023 were randomly selected as the research objects.According to the lottery method,they were divided into study group and control group,with 42 cases in each group.The study group was treated with salbutamol combined with budesonide,and the control group was treated with salbutamol.The dis-ease outcome,lung function,inflammatory factor level,symptom disappearance time and quality of life score were compared between the two groups.Results The disease outcome score of the study group was(21.02±3.89)points,which was higher than that of the control group(17.24±4.25)points,and the difference was statistically significant(t=4.251,P＜0.001).Before treatment,there was no significant difference in Asthma Control Test score,lung function in-dex,inflammatory factor level,symptom disappearance time and quality of life score between the two groups(all P＞0.05);after treatment,the lung function indexes and quality of life scores of the study group were higher than those of the control group,and the levels of inflammatory factors and symptom disappearance time were lower than those of the control group,the differences were statistically significant(all P＜0.05).Conclusion The effect of salbutamol combined with budesonide in patients with asthma and chronic obstructive pulmonary overlap syndrome is definite,which can better stabilize the patient's condition,improve the patient's lung function and improve the patient's quality of life.
Asthma and COPD overlap syndromeSalbutamolBudesonideClinical efficacy
NETL
NSTL
万方数据
